Targeting MyD88 Downregulates Inflammatory Mediators and Pathogenic Processes in PBMC From DMARDs-Naïve Rheumatoid Arthritis Patients is a research paper published in Frontiers in Pharmacology (2021). On theSindex it has a DataRank of 0. It has been cited 17 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Grant: R01 AR070736
National Institutes of Health
Grant: 5R01AR070736-07
Uncovering the role of Setbp1 in fibroblast-like synoviocytes during inflammatory arthritis
FWCI
2.16
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals
Additional file 1 of MyD88 dimerization inhibitor ST2825 targets the aggressiveness of synovial fibroblasts in rheumatoid arthritis patients
Additional file 1 of MyD88 dimerization inhibitor ST2825 targets the aggressiveness of synovial fibroblasts in rheumatoid arthritis patients
Additional file 3 of MyD88 dimerization inhibitor ST2825 targets the aggressiveness of synovial fibroblasts in rheumatoid arthritis patients
Additional file 2 of MyD88 dimerization inhibitor ST2825 targets the aggressiveness of synovial fibroblasts in rheumatoid arthritis patients
Additional file 3 of MyD88 dimerization inhibitor ST2825 targets the aggressiveness of synovial fibroblasts in rheumatoid arthritis patients
Additional file 2 of MyD88 dimerization inhibitor ST2825 targets the aggressiveness of synovial fibroblasts in rheumatoid arthritis patients